Talk to us: +977 1 4102891


Dosage Form:- Injection
Generic Name:- Furosemide 10mg/ml
Manufactured By:- National Healthcare Pvt. Ltd.


Amimide-P (Furosemide) injection is used to treat edema (fluid retention; excess fluid held in body tissues) caused by various medical problems, including heart failure, pulmonary edema (excess fluid in the lungs), kidney, and liver disease.

Therapeutic Class

Potent Diuretics

Dose and Direction of Use

Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.

The initial dose recommended for adults and adolescents over 15 years, is of 20 mg to 40 mg furosemide by intravenous administration; the maximum dose varying according to individual response.

If larger doses are required, they should be given increasing by 20 mg increments and not given more often than every two hours.

In adults, the recommended maximum daily dose of furosemide administration is 1500 mg.

The solution may be further diluted with a compatible carrier fluid, such as Sodium Chloride Injection B.P. or Ringer's Solution for Injection in which the rate of infusion should not exceed 4mg/minute.

The intravenous administration of furosemide to children and adolescents below 15 years is only recommended in exceptional cases. The dosage will be adapted to the body weight, and the recommended dose ranges from 0.5 to 1 mg/kg body weight daily up to a maximum total daily dose of 20 mg.

Mode of Action

Amimide-P (Furosemide) inhibits the co-transport system (reabsorption) of the following electrolytes Na+, Kand 2CL-, located on the luminal cell membrane on the ascending limb of the loop of Henle. As a result, the fraction of excreted sodium may ascend to 35% of sodium glomerular filtration. The secondary effects of increased elimination of sodium are: increase of urinary excretion and increase of potassium distal secretion at the distal tube. Excretion of calcium and magnesium salts is also increased.


When a prompt diuresis is required. Used in emergencies or when oral therapy is precluded. Indications include:

- Oedema and/or ascites caused by cardiac or hepatic diseases

- Oedema caused by renal diseases (in case of nephrotic syndrome, treatment of the underlying disease is essential)

- Pulmonary oedema (e.g. in case of acute heart failure)

- Hypertensive crisis (in addition to other therapeutic measures)


-  Hypersensitivity to the active substance or to any of the excipients.

– Patients with anuria or renal failure with oligoanuria not responding to furosemide

– Renal failure as a result of poisoning by nephrotoxic or hepatotoxic agents

– Renal failure associated with hepatic coma

– Patients with severe hypokalaemia or severe hyponatraemia

– Patients with hypovolaemia (with or without hypotension) or dehydration

– Patients with hypersensitivity to sulphonamides (e.g. Sulfonyureas or antibiotics of sulphonamides group) may show cross-sensitivity to furosemide

– Lactation

Precautions and Warning

  • Careful monitoring is required in case of:

Patients with partial obstruction of urinary outflow (e.g. prostatic hypertrophy, hydronephrosis, ureterostenosis). Urinary output must be secured

Patients with hypotension or at increased risk from pronounced fall in blood pressure 

Patients with manifest or latent diabetes mellitus or variation of glycaemia (regular monitoring of blood glucose levels necessary)

Patients with gout and hyperuricaemia (regular monitoring of uric acid levels in serum necessary)

Patients with hepatic disease or hepatorenal syndrome (renal impairment associated to severe hepatic disease)

- In cases of ascites with oedema, weight loss induced by enhanced diuresis should not exceed 1 kg / day

- Too vigorous diuresis may cause orthostatic hypotension or acute hypotensive episodes.

  • Talk to your doctor about adding potassium to your diet as this medication can reduce potassium level in the body.
  • If patient is diabetic, it is important to check on the blood sugar level.

This medicine has been viewed 56 times and last modified on 2021-01-18 14:10:32

National Healthcare Pvt. Ltd.